Market closed
Insulet/$PODD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Ticker
$PODD
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,000
Website
Insulet Metrics
BasicAdvanced
$19B
Market cap
47.91
P/E ratio
$5.74
EPS
1.22
Beta
-
Dividend rate
Price and volume
Market cap
$19B
Beta
1.22
52-week high
$271.24
52-week low
$160.19
Average daily volume
603K
Financial strength
Current ratio
3.676
Quick ratio
2.525
Long term debt to equity
125.152
Total debt to equity
128.909
Interest coverage (TTM)
8.50%
Management effectiveness
Return on assets (TTM)
7.57%
Return on equity (TTM)
48.79%
Valuation
Price to earnings (TTM)
47.909
Price to revenue (TTM)
9.696
Price to book
17.24
Price to tangible book (TTM)
19.94
Price to free cash flow (TTM)
88.154
Growth
Revenue change (TTM)
27.42%
Earnings per share change (TTM)
232.93%
3-year revenue growth (CAGR)
24.13%
3-year earnings per share growth (CAGR)
135.20%
What the Analysts think about Insulet
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Insulet Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Insulet Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Insulet News
AllArticlesVideos
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Reuters·6 days ago
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
Business Wire·1 week ago
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $19B as of December 12, 2024.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 47.91 as of December 12, 2024.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.